☆ 4.5 Article

Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Impact of interferon beta exposure on birth outcome and child development-Results from the post-authorisation safety study PRIMA

Juliane Klehmet et al.

Summary: This study examined the pregnancy and child development outcomes in women with multiple sclerosis (MS) treated with peginterferon beta-1a or intramuscular (IM) interferon beta-1a. The results showed that interferon beta therapies had no adverse effects on intrauterine growth and child development. These findings support the label update of all interferon beta therapies.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

添加到收藏夹

Article Clinical Neurology

Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn characteristics in a register-based cohort study in Finland and Sweden

Marta Korjagina et al.

Summary: This study aimed to describe the prevalence of adverse pregnancy outcomes among women with multiple sclerosis exposed to interferon-beta compared to those unexposed to any MS disease modifying drugs, and found that the prevalence of serious adverse pregnancy outcomes did not significantly differ between the two groups across various characteristics.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Review Clinical Neurology

Treatment of Women with Multiple Sclerosis Planning Pregnancy

Kristen M. Krysko et al.

Summary: This review examines the available data on treating multiple sclerosis (MS) before, during, and after pregnancy, focusing on disease-modifying therapies (DMTs). Injectable DMTs are recommended during pregnancy, while monoclonal antibodies like rituximab or natalizumab before pregnancy may also be safe options. Breastfeeding is associated with reduced risk of postpartum relapses, and further research on DMT safety during pregnancy is needed.

CURRENT TREATMENT OPTIONS IN NEUROLOGY (2021)

添加到收藏夹

Review Clinical Neurology

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)

Stanley L. Cohan et al.

Summary: Recombinant interferon was approved as first disease-modifying therapy for MS in 1993, with clinical trials demonstrating its effectiveness. Intramuscular IFN beta-1a has higher patient adherence and lower adverse reactions compared to subcutaneous formulations. MRI studies show that IFN beta-1a treatment reduces lesions, but the benefits of high-efficacy therapies need to be balanced against potential risks.

CNS DRUGS (2021)

添加到收藏夹

Review Clinical Neurology

Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies

Isabella Laura Simone et al.

Summary: Multiple sclerosis predominantly affects young women, impacting fertility, pregnancy, fetal outcome, and breastfeeding. The use of disease-modifying therapies has changed the natural history of the disease and perspectives on pregnancy.

FRONTIERS IN NEUROLOGY (2021)

添加到收藏夹

Review Clinical Neurology

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Heinz Wiendl et al.

Summary: The article discusses multiple sclerosis as a complex autoimmune disease of the central nervous system, highlighting the recent approval of disease-modifying therapies and increased understanding of disease mechanisms that have significantly altered the prognosis and course of the disease. The update from the Multiple Sclerosis Therapy Consensus Group focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021, based on current scientific evidence and applicable to wide parts of Europe, particularly German-speaking countries.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

The MSBase pregnancy, neonatal outcomes, and women's health registry

Vilija G. Jokubaitis et al.

Summary: The article discusses key considerations in managing women with multiple sclerosis in family planning and pregnancy decisions as well as existing knowledge gaps. It introduces the new MSBase pregnancy, neonatal outcomes, and women's health registry as a reference for future studies.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study

Til Menge et al.

Summary: This study investigated the adherence and efficacy of peginterferon beta-1a treatment in patients with relapsing-remitting multiple sclerosis. The majority of patients showed high adherence, low relapse rate, increased treatment satisfaction and convenience compared to previous therapies. Patient participation in support programs was associated with improved adherence, but the extent of influence was inconclusive. Clinical disease activity remained low and peginterferon beta-1a was well tolerated without new relevant safety findings.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry

Kerstin Hellwig et al.

JOURNAL OF NEUROLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study

Florian Lenz et al.

ADVANCES IN THERAPY (2020)

添加到收藏夹

Review Clinical Neurology

Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses A Systematic Review and Meta-analysis

Kristen M. Krysko et al.

JAMA NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort

Annette Langer-Gould et al.

NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Safety of potential breast milk exposure to IFN-β or glatiramer acetate One-year infant outcomes

Andrea Ines Ciplea et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

添加到收藏夹

Article Clinical Neurology

Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden

Katja Marja Hakkarainen et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2020)

添加到收藏夹

Review Immunology

Impact of sex hormones on immune function and multiple sclerosis development

Maria C. Ysrraelit et al.

IMMUNOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis

Sarah Burkill et al.

PLOS ONE (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Interferon β for Multiple Sclerosis

Dejan Jakimovski et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Treatment of multiple sclerosis during pregnancy - safety considerations

Jan Thoene et al.

EXPERT OPINION ON DRUG SAFETY (2017)

添加到收藏夹

Article Clinical Neurology

Interferon-beta exposure during first trimester is safe in women with multiple sclerosisA prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry

Sandra Thiel et al.

MULTIPLE SCLEROSIS JOURNAL (2016)

添加到收藏夹

Article Clinical Neurology

Interferon-beta exposure during first trimester is safe in women with multiple sclerosisA prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry

Sandra Thiel et al.

MULTIPLE SCLEROSIS JOURNAL (2016)

添加到收藏夹

Article Clinical Neurology

Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program

Zaza Katsarava et al.

BMC NEUROLOGY (2015)

添加到收藏夹

Review Clinical Neurology

Multiple sclerosis and pregnancy in the 'treatment era'

Sandra Vukusic et al.

NATURE REVIEWS NEUROLOGY (2015)

添加到收藏夹

Article Clinical Neurology

Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses

Kerstin Hellwig et al.

JAMA NEUROLOGY (2015)

添加到收藏夹

Article Clinical Neurology

Pregnancy in Multiple Sclerosis

Kerstin Hellwig

EUROPEAN NEUROLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events

P. K. Coyle et al.

BMJ OPEN (2014)

添加到收藏夹

Article Public, Environmental & Occupational Health

MONITORING OF CONGENITAL ANOMALIES IN LATVIA

Irisa Zile et al.

CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH (2014)

添加到收藏夹

Article Obstetrics & Gynecology

Transfer of Interferon β-1a into Human Breastmilk

Thomas W. Hale et al.

BREASTFEEDING MEDICINE (2012)

添加到收藏夹

Article Pharmacology & Pharmacy

A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

Xiao Hu et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2012)

添加到收藏夹

Letter Clinical Neurology

Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis

Kerstin Hellwig et al.

JOURNAL OF NEUROLOGY (2011)

添加到收藏夹

Article Obstetrics & Gynecology

Spontaneous abortion:: A prospective cohort study of younger women from the general population in Denmark.: Validation, occurrence and risk determinants

L Buss et al.

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2006)

添加到收藏夹

Article Clinical Neurology

Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse

S Vukusic et al.

BRAIN (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.